Advanced Search

 

Study ID Status Title Patient Level Data
116101 Completed Non-randomised, open label, multi-centre Phase II study to assess the efficacy and safety of SB-497115-GR in thrombocytopenic subjects with chronic hepatitis C and compensated liver cirrhosis.
116103 Active, Not Recruiting PGx421:Exploratory genetic evaluation of efficacy and safety endpoints in pazopanib-treated patients with soft tissue sarcoma in VEG110727
116108 Completed A Single-Dose, Randomised, Open-Label, Two-Period Crossover Study to Determine the Bioequivalence of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in the Fed State in Healthy Adult Male Subjects
116115 Completed A prospective study of sexual function in sexually active men treated for BPH
116119 Completed An open label, randomized, parallel, single dose study to investigate safety and pharmacokinetics following intravenous administration and subcutaneous administration of GSK1550188 in healthy Japanese males Study Listed on ClinicalStudyDataRequest.com
116125 Completed PGx:Meta-Analysis for change in blood pressure as a biomarker of pazopanib (GW786034) efficacy in advanced/metastatic renal cell carcinoma (VEG102616,VEG105192,VEG107769,PGx457)
116132 Completed A Randomized, Double-Blind, 3-Way, Cross-Over Study to Evaluate Lung Function Response after Treatment with Umeclidinium 62.5 mcg, Vilanterol 25 mcg, and Umeclidinium/Vilanterol 62.5/25 mcg Once-Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
116133 Completed A Randomized, Double-Blind, 3-Way, Cross-Over Study to Evaluate Lung Function Response after Treatment with Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg Once-Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
116134 Completed DB2116134: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy and Safety of Umeclidinium bromide/Vilanterol Compared with Fluticasone propionate/Salmeterol Over 12 weeks in Subjects with COPD Study Listed on ClinicalStudyDataRequest.com
116135 Completed A multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of the addition of umeclidinium bromide (62.5mcg) once-daily to fluticasone propionate/salmeterol (250/50mcg) twice-daily, umeclidinium bromide (125mcg) once-daily to fluticasone propionate/salmeterol (250/50mcg) twice-daily versus placebo to fluticasone propionate/salmeterol (250/50mcg) twice-daily over 12 weeks with COPD Study Listed on ClinicalStudyDataRequest.com
116136 Completed A multicenter, randomized, double-blind, parallelgroup study to evaluate the efficacy and safety of the addition of umeclidinium bromide Inhalation Powder (62.5mcg) once-daily to fluticasone propionate/salmeterol (250/50mcg) twice-daily, umeclidinium bromide Inhalation Powder (125mcg) once-daily to fluticasone propionate/salmeterol (250/50mcg) twice-daily versus placebo to fluticasone propionate/salmeterol (250/50mcg) twice-daily over 12 weeks in subjects with COPD. Study Listed on ClinicalStudyDataRequest.com
116144 Completed A relative bioavailability study of two formulations of topiramate 100 mg coated tablet in healthy male volunteers, the test formulation produced by Dr. Reddy's Laboratories Ltd. and the reference formulation (Topamax®) marked by Janssen-Cilag Farmacêutica Ltda.
116145 Completed Genotypic analysis of baseline and nadir HCV samples from subjects enrolled in the HBI115040 Phase I clinical trial
116146 Completed A retrospective analysis of the IL28 polymorphism of HCV-infected subjects enrolled in the HBI115040 Phase 1 clinical trial
116154 Completed PGx: A retrospective analysis of the IL28 polymorphism of HCV patients enrolled in the HAI114885 Phase 1 clinical trial
116156 Completed PGx: Further genotypic analysis of HCV patient samples from the HAI114885 Phase 1 clinical trials
116157 Completed PGx: Genotypic and phenotypic analysis of baseline and nadir HCV patient samples from HAI114885 Phase I clinical trials
116158 Terminated An open label study to evaluate the effects of ezogabine/retigabine added to existing anti-epileptic drug(s) on urinary voiding function in subjects with partial onset seizures
116160 Terminated A two part study to evaluate the safety, tolerability, and pharmacokinetics of GSK2251052 after single ascending dosesand repeat doses of IV GSK2251052 in healthy male Japanese and Caucasian subjects and a repeat dose study to evaluatesupratherapeutic doses of IV GSK2251052 in healthy volunteers
116170 Completed A 52-Week, Open-Label, Multicenter Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination with Monotherapy of Oral Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus Study Listed on ClinicalStudyDataRequest.com
116181 Completed A Phase 1, Open-Label, Crossover Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects
116196 Completed Retrospective study - Tissue Biomarker Study: Shaping Treatment in Melanoma
116197 Completed A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to Placebo (PM1116197) LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE (LATITUDE)-TIMI 60. Study Listed on ClinicalStudyDataRequest.com
116216 Completed An interaction study to assess the effect of the ezogabine/retigabine and the main metabolite NAMR on the pharmacokinetics of digoxin in healthy volunteers Study Listed on ClinicalStudyDataRequest.com
116235 Terminated Validation and Dosimetry Study of [18F]-FBA-A20FMDV2 PET Ligand for alpha(V)beta6 in Healthy Subjects and in the Lungs of Idiopathic Pulmonary Fibrosis (IPF) Subjects (PETAL study)

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.